Advertisement

Product › Details
AlphaDirect™ Lead-212 (Pb-212) isolation technology
![]() |
Next higher product group | RADIOPHARMACEUTICAL_o |
![]() |
Status | 2024-01-08 existent |
Eckert & Ziegler AG. (1/8/24). "Press Release: Eckert & Ziegler and ArtBio Announce Manufacturing and Supply Partnership for Lead-212 Conjugates". Berlin & Cambridge, MA.
Eckert & Ziegler (ISIN DE0005659700, SDAX) and ARTBIO, Inc. (ARTBIO), a clinical-stage biotechnology company specializing in the development of a new class of alpha radioligand therapies (ARTs), have entered into a strategic manufacturing and supply agreement. Under the collaboration Eckert & Ziegler will support ARTBIO to establish manufacturing and delivery of its pipeline therapies using its proprietary AlphaDirect™ Lead-212 (Pb-212) isolation technology.
The collaboration aims to expedite the development of Lead-212 based alpha radioligand therapies, starting with the clinical development of ARTBIO’s lead asset of AB001 in prostate cancer. Initially focussing on the US market and utilizing Eckert & Ziegler’s facilities in Boston, both companies plan to evaluate a global operations expansion at a later stage. Besides the US, Eckert & Ziegler’s global CMO service network includes manufacturing sites in Berlin, Germany and Jintan, China.
The radioisotope Lead-212 is an alpha precursor used as an active substance in cancer treatment. As part of a radiopharmaceutical product, the radioisotope enables precision treatment of tumor cells, while minimizing the damage to healthy adjacent tissue. With several studies ongoing, Pb-212-labeled compounds represent one of the most promising therapeutic approaches in nuclear medicine.
"We are excited to collaborate with ARTBIO in this transformative venture,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler. ”By combining Eckert & Ziegler's expertise in radiopharmaceutical manufacturing with ARTBIO's innovative approach to therapeutic solutions, we are poised to make substantial progress in advancing Lead-212 based alpha therapies."
"We are pleased to partner with Eckert & Ziegler to expand our distributed manufacturing network in order to reliably and efficiently deliver alpha radioligand therapies to patients," said Conrad Wueller, Director, Strategy and Operations at ARTBIO. "Eckert & Ziegler's vast experience and global footprint in radiopharmaceutical manufacturing and distribution will be critical as we advance our pipeline and aim to get our therapeutic candidates to people who need them most."
About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.
About ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb-212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company's AlphaDirect™ technology, a first-of-its-kind Pb-212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing three pipeline programs with lead program AB001 currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway's Radium Hospital.
Contact
Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Deutschland
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
[email protected] / [email protected]
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
ARTBIO
Amanda Breeding
[email protected]
+1 615-457-4734
Record changed: 2024-01-15 |
Advertisement

More documents for RADIOPHARMACEUTICAL (RPT)
- [1] Biosaxony e. V.. (1/16/25). "Press Release: Radiation Made in Saxony – Saxon Radiopharmacy Network nukliD Strengthens International Visibility"....
- [2] ITM Isotope Technologies Munich SE. (1/16/25). "Press Release: Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO". Chalk River, ON....
- [3] Eckert & Ziegler SE. (1/14/25). "Press Release: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture". Berlin....
- [4] Eckert & Ziegler SE. (1/13/25). "Press Release: Eckert & Ziegler and GlyTherix Extend Collaboration with Actinium-225 Supply Agreement". Berlin & Sydney....
- [5] ITM Isotope Technologies Munich SE. (1/13/25). "Press Release: ITM and Ariceum Therapeutics Enter into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225". Garching, Munich & Berlin....
- [6] ITM Isotope Technologies Munich SE. (12/13/24). "Press Release: ITM to Present at the 43rd Annual J.P. Morgan Healthcare Conference". Garching / Munich....
- [7] Siemens Healthineers AG. (12/10/24). "Press Release: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging"....
- [8] Eckert & Ziegler SE. (12/5/24). "Press Release: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments". Berlin....
- [9] Eckert & Ziegler SE. (12/3/24). "Press Release: Eckert & Ziegler – Changes in the Executive Board and Supervisory Board". Berlin....
- [10] |transkript [Kääb, Georg]. (9/24/24). "First German Life Sciences IPO since 2016 – Radiopharma Company Pentixapharm Lists at Frankfurt Stock Exchange. Interview by |transkript.de/Georg Kääb with Andreas Eckert"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top